Satellite Symposia

Satellite Symposia Schedule

Satellite Symposia Schedule

Thank you for registering for the 2024 Crohn’s & Colitis Congress®. While you’re at the Congress, you can take advantage of any of the following satellite symposia. Please be sure to register for each one separately. 

Navigating the New Treatment Landscape for Inflammatory Bowel Disease

Thursday, January 19, 7:00–8:30 p.m.

In partnership with Medscape. Supported by an educational grant from AbbVie.

Faculty

  • Russell D. Cohen, MD, AGAF
  • Ryan C. Ungaro, MD, MS
  • Sandra Quezada, MD, MS, AGAF

 

Learning Objectives

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the:
    • Mechanisms of action of newer targeted treatments for IBD.
    • Clinical data on newer targeted IBD treatments.
  • Have greater competence related to:
    • Recommending evidence-based IBD treatments that consider patients’ comorbid conditions. 
    • Utilizing appropriate laboratory monitoring prior to and during treatment with newer targeted IBD agents.
  • Greater confidence in their ability to
    • Incorporate new targeted agents for IBD into treatment strategies

What They Say and What They Think: Exploring Tools for Assessing Bowel Urgency in Patients with Ulcerative Colitis

Friday, January 20, 6:00–7:30 a.m.

In partnership with PeerVoice. Supported by an educational grant from Lilly.

Faculty

  • David T. Rubin, MD, AGAF
  • Marla C. Dubinsky, MD
  • Adam Benjamin, MD – patient advocate

 

Learning Objectives

As a result of this activity, learners should be able to:

  • Discuss latest evidence on bowel urgency in patients with ulcerative colitis (UC) and its influence on quality of life.
  • Analyze current communication gaps between patients with UC and clinicians during clinic visits.
  • Recognize the benefits and limitations of current patient-reported outcomes tools.

Back to Basics – Examining Mechanisms of New IBD Therapies

Friday, January 20, 12:15–1:45 p.m.

In partnership with CME Outfitters, LLC. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Faculty

  • Marla Dubinsky, MD – moderator
  • Sara Horst, MD, MPH
  • Gil Y. Melmed, MD, MS, AGAF

 

Learning Objectives

  • Incorporate evidence-based clinical, biomarker, and endoscopic treatment targets into clinical practice when developing treatment goals for patients with IBD.
  • Develop treatment plans based on comparative efficacy and safety data for biologic-naïve and biologic-experienced patients with IBD.
  • Engage an interprofessional team to improve patient care and IBD treatment outcomes.

Out of the Shadows: Starting the Conversation About Bowel Urgency in Patients with Crohn’s Disease

Thursday, January 25, 5–6:30 p.m.

In partnership with CME Outfitters, LLC. This activity is supported by an educational grant from Lilly.

Faculty
Marla Dubinsky, MD – moderator
Tauseef Ali, MD, FACP, FACG, AGAF
Millie Long, MD, MPH

Learning Objectives
At the conclusion of this activity, learners will be able to better:

  • Recognize the frequency of bowel urgency in patients with CD and the impact on patient quality of life.
  • Incorporate assessments for bowel urgency as part of thorough symptom evaluation for patients with CD.
  • Engage patients in open communication about their bowel urgency as part of shared decision-making in order to improve clinical outcomes.
  

Clean-Up on IL-23: Integrating the Science of Inflammatory Targets into Treatment Decision-making in IBD

Friday, January 26, 12:30–2 p.m.

In partnership with CME Outfitters, LLC. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Faculty
Maria T. Abreu, MD – moderator
Jessica R. Allegretti, MD, MPH, FACG, AGAF
David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh)

Learning Objectives
At the conclusion of this activity, learners will be able to better:

  • Assess the role of various pro-inflammatory cytokines to inflammation in the pathogenesis of IBD.
  • Classify the role of the IL-23 and Th17 pathway in IBD pathogenesis.
  • Evaluate the potential clinical implications of CD64 receptor binding by anti-IL-23 mAbs in the treatment of IBD.

The Crohn’s & Colitis Congress® will offer four live, in-person symposia slots. Satellite symposia slots will be filled on a first-come, first-served basis via an online application. All symposiums will occur during breakfast or lunch times.

All satellite symposia are accredited by AGA. Proposals submitted to grant offices without going through this RFP process will not be accepted as Congress affiliated programming.

Schedule

Date Time Supporter
Thursday, Jan. 25 5:00–6:30 p.m. Lilly USA
Friday, Jan. 26 12:30–2:00 p.m. Janssen Biotech, Inc.

General Information

The Crohn’s & Colitis Congress® will offer two live, in-person symposia slots. Satellite symposia slots will be filled on a first-come, first-served basis via an online application. All symposiums will occur during breakfast or lunch times.

All satellite symposia are accredited by CME Outfitters, LLC. Proposals submitted to grant offices without going through this RFP process will not be accepted as Congress affiliated programming.

For more information, please contact Dana Johnston.

Date Time Supporter
Thursday, Jan. 25 5:00–6:30 p.m. Lilly USA
Friday, Jan. 26 12:30–2:00 p.m. Janssen Biotech, Inc.

This website uses cookies to provide you with the best experience on our website. If you wish to disable cookies, please do so in your browser settings. Your continued use of our site without disabling your cookies is subject to the cookie policy. Learn More